logo-loader
HealthPharma & Biotech
Redx Pharma Plc

Redx receives regulatory green light to restart research

It means the company is on track to restart the phase I/II study of its next-generation cancer treatment as planned in the first-half

go sign
The company received the go ahead from the UK’s Medicines and Healthcare products Regulatory Agency

Redx Pharma Plc (LON:REDX) saw its shares jump on Monday after the firm said it had received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.

It means the company is on track to restart the study as planned in the first-half.

RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.

READ: First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

Patients receiving the oral medication will do so at much lower starting doses than originally planned.

“We have learnt a significant amount from the first patient treated with RXC004, and this provides the basis for an optimised RXC004 development plan as well as the confidence to evaluate the clinical potential of RXC004 in cancer patients,” said Natalie Cook, consultant oncologist and principal investigator from the Christie Hospital in Manchester.

Redx chief executive Lisa Anson said she believes the putative treatment has potential used on its own and in combination with standard of care treatments.

“We look forward to working closely with our expert clinical oncology colleagues across the U.K. on this exciting programme,” she added.

In early morning trading, Redx shares were 10.7% higher at 7.75p.

 -- Adds share price --

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £11.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18

2 min read